Pfizer
NEWS
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
Since Allogene Therapeutics launched in April the company has been rapidly expanding its leadership team as it drives forward with a mission of developing allogeneic CAR-T therapies.
Novartis has walked into the European Congress of Rheumatology to make a case for two of its drugs, Cosentyx and canakinumab.
ViiV Healthcare, established in November 2009 by GlaxoSmithKline, Pfizer and Shiongi, reported positive results from its Phase III GEMINI-1 and -2 clinical trials.
AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.
The U.S. Food and Drug Administration (FDA) recently reprimanded AbbVie for its processes for investigating reports of deaths associated with three of its drugs.
Gilmore O’Neill, formerly Biogen’s senior vice president, late-stage clinical development, jumped ship and will be Sarepta Therapeutics’ chief medical officer.
Biogen signed an exclusive option deal with Tokyo-based TMS for TMS-007 and backup compounds.
BioMarin Pharmaceutical received $20 million in milestone payments from Pfizer after the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved its applications for talazoparib.
JOBS
IN THE PRESS